Combination regimens using doxorubicin and pegylated liposomal doxorubicin prior to autologous transplantation in multiple myeloma

Expert Review of Anticancer Therapy

Volumn 9, Issue 7, 2009, Pages 885-890

  Moreau, Philippe ^a  

^a HÔTEL DIEU   (France)

Author keywords

Anthracycline; Autologous stem cell transplantation; Doxorubicin; Induction therapy; Multiple myeloma; Pegylated liposomal doxorubicin

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; LIPOSOME; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ALOPECIA; ARTICLE; ASTHENIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEDTIME DOSAGE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CARDIOTOXICITY; CATHETER INFECTION; CATHETER THROMBOSIS; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG FORMULATION; DRUG POTENTIATION; DRUG TOLERABILITY; EDEMA; EVENT FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; STEM CELL MOBILIZATION; THROMBOCYTOPENIA;

EID: 69249175222     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.09.52     Document Type: Article

References (41)

1. Alberts DS, Salmon SE. Adriamycin (NSC.123127) in the treatment of alkylator-resistant multiple myeloma: a pilot study. Cancer Chemother. Rep. 59, 345 (1975).
2. Rödjer S, Nilsson B, Westin J. Do anthracyclines have a role in the therapy of multiple myeloma? Hematol. J. 1, 422-426 (2000).
3. Alexanian R, Barlogie B, Tucker S. VAD-based regimens as primary treatment for multiple myeloma. Am. J. Hematol. 33, 86-89 (1990).
4. Anderson H, Scarffe JH, Ranson M et al. VAD chemotherapy as remission induction for multiple myeloma. Br. J. Cancer 71, 326-330 (1995).
5. Segeren CM, Sonneveld P, van der Holt B et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma. Br. J. Haematol. 105, 127-130 (1999).
6. Cavo M, Zamagni E, Tosi P et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicin dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 106, 35-39 (2005).
7. Lokhorst HM, Schmidt-Wolf I, Sonneveld P et al. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93, 124-127 (2008).
8. Attal M, Harousseau JL, Leyvraz S et al. Maintenance therapy with thalidomide improves survival in multiple myeloma patients. Blood 15, 3289-3294 (2006).
9. Moreau P, Hulin C, Garban F et al. Tandem autologous stem cell transplantation in high-risk de novo; multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood, 397-403 (2006).
10. Macro M, Divine M, Uzunhan Y et al. Dexamethasone plus thalidomide compared to VAD as a pre-transplanttreatment in newly diagnosed multiple myeloma. Blood 108 (2006) (Abstract 57).
11. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 106, 848-858 (2006).
12. Hussein MA, Wood L, Hsi E et al. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients. Cancer 95, 2160-2168 (2002).
13. Dimopoulos MA, Pouli A, Zervas K et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann. Oncol. 14, 1039-1044 (2003).
14. Porter CA, Rifkin RM. Clinical benefis and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma. Clin. Lymphoma Myeloma 7(Suppl. 4), S150-S155 (2007).
15. Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 80, 887-890 (1992).
16. Rajkumar SV, Hayman S, Gertz MA et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J. Clin. Oncol. 20, 4319-4323 (2002).
17. Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J. Clin. Oncol. 21, 16-19 (2003).
18. Cavo M, Zamagni E, Tosi P et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89, 826-831 (2004).
19. Rajkumar SV. Multiple myeloma: the death of VAD as initial therapy. Blood 106, 2-3 (2005).
20. Lokhorst H, van der Holt B, Zweegmann S et al. Final analysis of HOVON-50 randomized Phase III study on the effect of thalidomide combined with adriamycine, dexamethasone and high-dose melphalan in patients with multiple myeloma. Blood 112, 157a (2008) (Abstract).
21. Lahuerta JJ, Mateos MV, Martinez-Lopez J et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 26, 5775-5782 (2008).
22. Offidani M, Bringhen S, Corvatta L et al. Thalidomide - dexamethasone plus pegylated liposomal doxorubicin vs thalidomide - dexamethasone: a case-matched study in advanced multiple myeloma. Eur. J. Haematol. 78, 297-302 (2007).
23. Zervas K, Dimopoulos MA, Hatzicharissi E et al. Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a Phase II multicenter study. Ann. Oncol. 15, 134-138 (2004).
24. Zervas K, Mihou D, Katodritou E et al. VAD - doxil versus VAD - doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group. Ann. Oncol. 18, 1369-1375 (2007).
25. Jagannath S, Durie B, Wolf J et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br. J. Haematol. 129, 776-783 (2005).
26. Harousseau JL, Attal M, Leleu X et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma. Haematologica 91, 1498-1505 (2006).
27. Rosinol L, Oriol A, Mateos MV et al. Phase II pethema trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics. J. Clin. Oncol. 25, 4452-4458 (2007).
28. Harousseau JL, Mathiot C, Attal M et al. Velcade/dexamethasone versus VAD as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma: updated results of the IFM 2005/01 trial. Blood 110, 139a (2007) (Abstract).
29. Mitsiades N, Mitsiades C, Richardson P et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101, 2377-2380 (2003).
30. Ma MH, Yang HH, Parker K et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin. Cancer Res. 9, 1136-1144 (2003).
31. Orlowski RZ, Voorhees PM, Garcia RA et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105, 3058-3065 (2005).
32. Orlowski RZ, Nagler A, Sonneveld P et al. Randomized Phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed, refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol. 25, 3892-3901 (2007).
33. Bladé J, Sonneveld P, San Miguel JF et al.; DOXIL-MMY-3001 Study Investigators. Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment. Clin. Lymphoma Myeloma 8, 352-355 (2008).
34. Sonneveld P, Hajek R, Nagler A et al.; DOXIL-MMY-3001 Study Investigators. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy. Cancer 112, 1529-1537 (2008).
35. Oakervee E, Popat R, Curry N et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br. J. Haematol. 129, 755-762 (2005).
36. Popat R, Oakervee E, Hallam S et al. Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br. J. Haematol. 141, 512-516 (2008).
37. Jakubowiak AJ, Al-Zoubi A, Kendall T et al. High rate of complete and near-complete responses after initial therapy with bortezomib, doxil and dexamethasone is further increased after autologous stem cell transplantation. Blood 108, 3093a (2006) (Abstract).
38. Palumbo A, Falco P, Gay F et al. Bortezomib - doxorubicin - dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation/maintenance in elderly untreated myeloma patients. Blood 112, 159a (2008) (Abstract).
39. Sonneveld P, van der Holt B, Schmidt-Wolf IGH et al. First analysis of HOVON-65/GMMG-HD4 randomized Phase III trial comparing bortezomib, adriamycine, dexamethasone (PAD) versus VAD as induction treatment prior to high dose melphalan in patients with newly diagnosed multiple myeloma. Blood 112, 653a (2008) (Abstract).
40. Cavo M, Tacchetti P, Patriarca F et al. Superior complete response rate and progression-free survival after autologous transplantation with upfront velcade - thalidomide - dexamethasone compared with thalidomide - dexamethasone in newly diagnosed multiple myeloma. Blood 112, 158a (2008) (Abstract).
41. Richardson P, Lonial S, Jakubowiak A et al. Lenalidomide, bortezomib, and dexamethasone in patients with newly diagnosed multiple myeloma: encouraging efficacy in high risk groups with updated results of a Phase I/II study. Blood 112, 92a (2008) (Abstract).